Patent · US Active

Compounds for targeted degradation of BRD9

US12049464B2 · kind B2 · utility

0Cited by
21References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 1, 2022
Grant dateJul 30, 2024
Priority date
Expiry dateSep 1, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D487/08
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.